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Do Not Give Up
To the Editors:
Most women with advanced ovariancancer undergo cytoreductive sur-
gery and chemotherapy, enter a period
of follow-up, and ultimately relapse. Al-
though there are a number of therapeu-
tic interventions in this situation with at
least 7 active chemotherapy or biological
agents and the possibility of secondary
cytoreductive surgery, long-term survival
after relapse is rare and most women
succumb to their disease.1
We present a woman diagnosed with
an advanced ovarian cancer who had a
total of 22 relapses, 19 systemic treat-
ments, and 6 localized palliative inter-
ventions for over a 14-year period, which,
to the best of our knowledge, to more
therapy than has been described before.
She had no previous signiﬁcant medical
history but did have a positive family
history of ovarian cancer; her sister died
from the disease at the age of 48 years
and a paternal cousin developed ovarian
cancer in her 60s. On the basis of this,
she elected to undergo prophylactic
oophorectomies at the age of 46 years
but imaging before surgery revealed an
ovarian mass, which led to a pelvic clea-
rance and omentectomy, and she was
diagnosed with a stage 3 grade 3 endo-
metrioid carcinoma of the ovary. After
surgery, she had adjuvant chemotherapy
in the context of the SCOTROC3 study.2
She relapsed 7 months later rendering her
only partially platinum sensitive. Despite
this, she went on to receive platinum-
containing chemotherapy on 10 separate
occasions, and each time, this resulted
in a Ca125 marker and clinical response
(Fig. 1). In between and during most
treatments, shewas ﬁt and enjoyed a good
quality of life.
Interestingly, genetic screening on
the basis of her family history and her
repeated responses to platinum-based
chemotherapy did not reveal a BRCA
mutation when initially performed
around the time of diagnosis or when
repeated several years later with the as-
sumption that improved molecular tech-
niques would identify a mutation. It is
quite possible, however, that shewill have
had an as yet unidentiﬁed mutation
conferring ‘‘BRCAness’’ that may have
responded to Poly (ADP-ribose) poly-
merase inhibitors. Drugs used (Table 1) in
combination with platinum in her case in-
cludeetoposide, paclitaxel, andgemcitabine.
Drugs used as single agents included
oral altretamine, pegylated liposomal
doxorubicin, oral cyclophosphamide, and
tamoxifen. Nodal relapses were treated
with palliative radiotherapy to good effect
and she participated in 4 different clin-
ical trials. Her ﬁrst relapse was 7 months
after primary treatment and most of her
subsequent treatment free intervals were
between 4 and 6 months except after
2 clinical trials involving vascular dis-
ruptive agents (VDAs) where the in-
tervals were much longer (18 months
for combretastatin3 and 9 months after
OXI45034). The monoclonal antibody,
bevacizumab, and other antiangiogenic
agents have been investigated and have
a role in the treatment of ovarian cancer,
but this is 1 class of drugs to which she
was not exposed. The funding approval
FIGURE 1. Change in CA125 levels is response to therapy.
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for bevacizumab in the United Kingdom
was in the ﬁrst-line5 and platinum-
sensitive6 settings and did not apply
to this patient. It had been hoped that
she would remain well enough to enter
another VDA trial in combination with
pazopanib, an antiangiogenic tyrosine
kinase inhibitor (PAZOFOS, UKCRN
88145142), but sadly she died before the
study opened.
This case demonstrates that plati-
num resistance by conventional deﬁnition
does not mean that patients with ovarian
cancer will never respond to platinum in
the future and the role of VDAs, along-
side conventional antiangiogenics in the
management of this disease, is looked to
with interest.
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TABLE 1. Treatment given for each line of therapy
Relapse Relapse Date Treatment and No. Cycles Given
First line April 2000 Docetaxel/carboplatin (SCOTROC 3)
First relapse July 2001 Oral altretamine
Second relapse March 2002 Carboplatin  5
Third relapse September 2002 Cisplatin/etoposide (DD)  6 wk
Fourth relapse July 2003 CA4P/paclitaxel (combretastatin study)  6
Fifth relapse April 2005 Carboplatin  6
Sixth relapse January 2006 Pegylated liposomal doxorubicin  4
Seventh relapse June 2006 Carboplatin/paclitaxel  4
Eighth relapse February 2007 Radiotherapy to para-aortic nodes
Ninth relapse August 2007 DD carboplatin/paclitaxel  3
Allergic reaction, switch to DD cisplatin/paclitaxel  6
10th relapse March 2008 Tamoxifen
11th relapse July 2008 Gemcitabine/cisplatin  1 (stopped because of sickness and good response),
continued on maintenance tamoxifen
12 relapse May 2009 Radiotherapy to left SCF nodes (20Gy in 5#)
13th relapse July 2009 Gemcitabine/cisplatin  1
14th relapse October 2009 OXI4503 phase 1 trial (CA1P, vascular disrupting agent)  6
(18 infusions OXI4503)
Oral cyclophosphamide  2
15th relapse September 2010 Radiotherapy to right SCF nodes
16th relapse November 2010 DD carboplatin/paclitaxel  6
17th relapse January 2011 Pegylated irinotecan  6 (NEKTAR study)
18th relapse November 2011 Radiotherapy to left axilla (20Gy in 5#)
19th relapse July 2012 Gemcitabine/cisplatin  1
20th relapse February 2013 Gemcitabine/cisplatin  1
21st relapse June 2013 Radiotherapy to left neck nodes (20Gy in 5#) and oral cyclophosphamide  1
22nd relapse October 2013 DD weekly paclitaxel  3 interrupted by fractured humerus, further
radiotherapy to neck
Date of death November 06, 2014
DD indicates dose dense; SCF, supraclavicular fossa.
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